Onset Therapeutics has launched BenzEFoam (benzoyl peroxide 5.3%) emollient foam for the topical treatment of mild to moderate acne vulgaris. BenzEFoam spreads easily over extensive skin areas (eg, chest and back) where body acne symptoms most often occur. In a clinical trial, BenzEFoam demonstrated a greater than 100-fold reduction in Propionibacterium acnes counts after two weeks of use.

BenzEFoam is available in a 60g aluminum can.

For more information call (888) 713-8154 or visit www.benzefoam.com.